Genmab — Februar 2021
-
Seit Montag, dem 1. Februar 2021 ist Kesimpta
(Ofatumumab) mit folgender Indikation in der Schweiz zugelassen:• Zur Behandlung von erwachsenen Patienten mit aktiven schubförmigen Verlaufsformen der Multiplen Sklerose (MS) ; small,
but Novartis' home market -
the 'Public summary of opinion on orphan designation: Teclistamab...' via https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3202331
-
God morgen.
-
Asien: Kinesisk nytår holder de fleste markeder lukket - NYhttps://www.proinvestor.com/investornyt/672053/asien-kinesisk-nytar-holder-de-fleste-markeder-lukket-ny
-
Fredagens aviser med Novo Nordisk, GN og Rockwoolhttps://www.proinvestor.com/investornyt/672049/fredagens-aviser-med-novo-nordisk-gn-og-rockwool
-
Aktier: Pensionschefer tror på fortsat fremgang - GENT
https://www.proinvestor.com/investornyt/672054/aktier-pensionschefer-tror-pa-fortsat-fremgang-gent -
-
-
Det virker ikke som om det er bispefikke andibodies? Så kan de vel ikke være så potentente som Genmabs kandidater?
-
-
if someone here can take on this job of Director of Marketing (DOM), Multiple Myeloma Bi-specifics at JNJ pls, we'll have some inside info on teclistamab and talquetamab
https://jobs.jnj.com/jobs/2105898342W?lang=en-us -
You should take that E L.It is almost a local position for you - Pennsylvania Dutch
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind